Anti‐infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response
暂无分享,去创建一个
K. Van Steen | S. Vermeire | T. Van Stappen | A. Gils | M. Ferrante | G. Van Assche | G. Assche | V. Ballet | S. Tops | G. Compernolle | M. Peeters | E. Dreesen | T. V. Stappen | K. van Steen | S. Vermeire | Ann Gils | Marc Ferrante | Miet Peeters | K. V. D. Steen
[1] S. Vermeire,et al. Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial , 2017, Gut.
[2] S. Vermeire,et al. Immunoassay for Detection of Infliximab in Whole Blood Using a Fiber-Optic Surface Plasmon Resonance Biosensor. , 2017, Analytical chemistry.
[3] S. Vermeire,et al. DOP029 Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post-hoc analysis of the taxit trial. , 2017, Journal of Crohn's & colitis.
[4] R. Eliakim,et al. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab , 2017, Alimentary pharmacology & therapeutics.
[5] S. Vermeire,et al. Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation , 2016, Clinical and translational gastroenterology.
[6] A. Gonçalves,et al. Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point‐of‐care quantitative test with two established ELISA assays , 2016, Alimentary pharmacology & therapeutics.
[7] S. Bonovas,et al. Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[8] S. Vermeire,et al. Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment. , 2016, Current drug targets.
[9] N. Ding,et al. Systematic review: predicting and optimising response to anti‐TNF therapy in Crohn's disease – algorithm for practical management , 2016, Alimentary pharmacology & therapeutics.
[10] A. Amiot,et al. The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab , 2015, Alimentary pharmacology & therapeutics.
[11] T. Matsui,et al. Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical Trial , 2015, Inflammatory bowel diseases.
[12] Els Brouwers,et al. Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays , 2015, Therapeutic drug monitoring.
[13] K. Van Steen,et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. , 2015, Gastroenterology.
[14] B. Sands,et al. High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy. , 2015, Journal of Crohn's & colitis.
[15] L. A. Christensen,et al. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease. , 2015, Journal of Crohn's & colitis.
[16] T. Kitazono,et al. Therapeutic Strategy for Crohn's Disease with a Loss of Response to Infliximab: A Single-Center Retrospective Study , 2015, Digestion.
[17] A. Moss,et al. Editorial: adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease , 2014, Alimentary pharmacology & therapeutics.
[18] L. Dieleman,et al. Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease , 2014, Alimentary pharmacology & therapeutics.
[19] M. Silverberg,et al. Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease , 2013, Alimentary pharmacology & therapeutics.
[20] U. Kopylov,et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[21] J. Gisbert,et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response , 2012, Inflammatory bowel diseases.
[22] T. Matsui,et al. Retrieval of Serum Infliximab Level by Shortening the Maintenance Infusion Interval Is Correlated with Clinical Efficacy in Crohn's Disease , 2012, Inflammatory bowel diseases.
[23] J. Terdiman,et al. Durability of Infliximab Dose Intensification in Crohn’s Disease , 2012, Digestive Diseases and Sciences.
[24] J. Mate,et al. Intensification of infliximab therapy in Crohn's disease: efficacy and safety. , 2012, Journal of Crohn's & colitis.
[25] Leon Dent,et al. Next-gen sequencing of multi-drug resistant Acinetobacter baumanii at Nashville General Hospital at Meharry , 2011, BMC Bioinformatics.
[26] S. Ben-Horin,et al. Review article: loss of response to anti‐TNF treatments in Crohn’s disease , 2011, Alimentary pharmacology & therapeutics.
[27] Xavier Robin,et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.
[28] U. Kopylov,et al. The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab , 2011, Alimentary pharmacology & therapeutics.
[29] S. Schreiber,et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? , 2011, The American Journal of Gastroenterology.
[30] Pedro M. Valero-Mora,et al. ggplot2: Elegant Graphics for Data Analysis , 2010 .
[31] W. Sandborn,et al. Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease , 2010, The American Journal of Gastroenterology.
[32] Hadley Wickham,et al. ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .
[33] J. Gisbert,et al. Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review , 2009, The American Journal of Gastroenterology.
[34] G. Kaplan,et al. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost‐effectiveness analysis , 2007, Alimentary pharmacology & therapeutics.
[35] P. Rutgeerts,et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease , 2007, Gut.
[36] P. Rutgeerts,et al. Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.
[37] An Carbonez,et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.
[38] S. Hanauer,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[39] B. Scallon,et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. , 1993, Molecular immunology.
[40] John Fox,et al. Robust Regression in R An Appendix to An R Companion to Applied Regression, Second Edition , 2011 .
[41] Alan J. Miller,et al. leaps: Regression Subset Selection. , 2004 .